Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole
An Open-label Phase 1b Study of ARQ 092 in Combination With Other Antineoplastic Agents in Subjects With Selected Solid Tumors
Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Listed as NCT02476955, this PHASE1 trial focuses on Endometrial Cancer and Ovarian Cancer and remains terminated or withdrawn. Sponsored by ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA), it has been updated 14 times since 2015, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
14 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2024 — Jul 2024 [monthly]
Terminated PHASE1
-
Oct 2021 — Jan 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Oct 2021 [monthly]
Terminated PHASE1
▶ Show 9 earlier versions
-
Oct 2020 — Jan 2021 [monthly]
Terminated PHASE1
Status: Completed → Terminated · Phase: PHASE1_PHASE2 → PHASE1
-
Aug 2020 — Oct 2020 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
-
Jun 2019 — Aug 2020 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Feb 2019 — Jun 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Oct 2018 — Feb 2019 [monthly]
Recruiting PHASE1_PHASE2
Phase: PHASE1 → PHASE1_PHASE2
-
Jun 2018 — Oct 2018 [monthly]
Recruiting PHASE1
-
Mar 2018 — Jun 2018 [monthly]
Recruiting PHASE1
-
Feb 2017 — Mar 2018 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Jun 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
For direct contact, visit the study record on ClinicalTrials.gov .